Scholar Rock Holding Corporation $SRRK Stock Position Lifted by Squarepoint Ops LLC

Squarepoint Ops LLC grew its holdings in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK - Free Report) by 484.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 291,996 shares of the company's stock after purchasing an additional 242,041 shares during the period. Squarepoint Ops LLC owned 0.24% of Scholar Rock worth $16,060,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Siren L.L.C. lifted its holdings in Scholar Rock by 17.0% in the fourth quarter. Siren L.L.C. now owns 10,825,013 shares of the company's stock worth $476,842,000 after acquiring an additional 1,575,008 shares during the last quarter. BlackRock Inc. acquired a new stake in Scholar Rock in the second quarter worth $522,175,000. Redmile Group LLC lifted its stake in Scholar Rock by 73.7% in the first quarter. Redmile Group LLC now owns 9,066,621 shares of the company's stock valued at $445,715,000 after buying an additional 3,845,775 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Scholar Rock by 26.7% during the fourth quarter. Wellington Management Group LLP now owns 5,759,428 shares of the company's stock valued at $253,703,000 after acquiring an additional 1,213,541 shares during the period. Finally, California State Teachers Retirement System grew its position in shares of Scholar Rock by 6,187.6% during the second quarter. California State Teachers Retirement System now owns 4,710,420 shares of the company's stock worth $259,073,000 after acquiring an additional 4,635,504 shares during the last quarter. 91.08% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Katie Peng sold 5,446 shares of Scholar Rock stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $53.88, for a total value of $293,430.48. Following the transaction, the director directly owned 34,301 shares of the company's stock, valued at $1,848,137.88. This trade represents a 13.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Michael Gilman sold 2,544 shares of the business's stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $53.87, for a total transaction of $137,045.28. Following the sale, the director owned 59,511 shares in the company, valued at $3,205,857.57. This represents a 4.10% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 17,149 shares of company stock valued at $923,108. Company insiders own 10.30% of the company's stock.

Scholar Rock Stock Performance

NASDAQ:SRRK opened at $54.62 on Thursday. The company has a 50-day moving average of $53.53 and a 200-day moving average of $49.42. The firm has a market cap of $6.65 billion, a price-to-earnings ratio of -15.83 and a beta of 0.67. The company has a current ratio of 7.02, a quick ratio of 7.02 and a debt-to-equity ratio of 0.77. Scholar Rock Holding Corporation has a twelve month low of $27.07 and a twelve month high of $61.76.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.84) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.84). During the same period last year, the firm earned ($0.98) earnings per share. Analysts forecast that Scholar Rock Holding Corporation will post -3.23 earnings per share for the current fiscal year.

Analyst Ratings Changes

SRRK has been the topic of a number of analyst reports. BMO Capital Markets reaffirmed an "outperform" rating and issued a $76.00 price objective on shares of Scholar Rock in a report on Friday, August 7th. Cantor Fitzgerald restated an "overweight" rating on shares of Scholar Rock in a research note on Thursday, June 18th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Scholar Rock in a report on Friday, July 17th. HC Wainwright downgraded Scholar Rock from a "buy" rating to a "neutral" rating in a research report on Tuesday. Finally, JPMorgan Chase & Co. increased their price objective on Scholar Rock from $56.00 to $63.00 and gave the stock an "overweight" rating in a report on Thursday, August 13th. Four analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Buy" and an average price target of $58.77.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company's research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock's approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company's lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.